John Trizzino - Jun 25, 2022 Form 4 Insider Report for NOVAVAX INC (NVAX)

Role
EVP, CCO and CBO
Signature
/s/ John A. Herrmann III, Attorney-in-Fact
Stock symbol
NVAX
Transactions as of
Jun 25, 2022
Transactions value $
-$14,364
Form type
4
Date filed
6/28/2022, 05:06 PM
Previous filing
Mar 14, 2022
Next filing
Aug 23, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NVAX Common Stock Options Exercise +833 +24.7% 4.21K Jun 25, 2022 Direct F1
transaction NVAX Common Stock Tax liability -$14.4K -278 -6.61% $51.67* 3.93K Jun 25, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NVAX Restricted Stock Units Options Exercise $0 -833 -50% $0.00 833 Jun 25, 2022 Common Stock 833 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.
F2 The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the June 25, 2020 grant date, in each case subject to continued employment through such vesting date.